Financials Arrowhead Pharmaceuticals, Inc.

Equities

ARWR

US04280A1007

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 21:00:00 11/09/2024 BST			5-day change	1st Jan Change
20.94 ^USD	-2.47%		-12.68%	-31.57%

09-10	Arrowhead Pharmaceuticals' Plozasiran Receives FDA Breakthrough Therapy Designation	MT
09-10	Arrowhead Pharmaceuticals Gets FDA Breakthrough Designation for Plozasiran	DJ

Projected Income Statement: Arrowhead Pharmaceuticals, Inc.

Fiscal Period: September	2019	2020	2021	2022	2023	2024	2025	2026
Net sales ¹	168.8	87.99	138.3	243.2	240.7	61.6	150.6	230.6
Change	-	-47.87%	57.16%	75.89%	-1.03%	-74.41%	144.42%	53.15%
EBITDA ¹	-	-87.22	-140.8	-168.1	-192.5	-535.9	-544.3	-520.5
Change	-	-	61.4%	19.41%	14.53%	-178.38%	-1.56%	4.37%
EBIT ¹	61.19	-93.16	-149	-178.5	-205	-558.2	-547.1	-500.9
Change	-	-	59.98%	19.77%	14.84%	-172.3%	2%	8.45%
Interest Paid ¹	-	-	-	-	-1.489	-10.78	-26.1	-0.2
Earnings before Tax (EBT) ¹	61.19	-84.55	-140.8	-172.7	-206.5	-554	-505.8	-455.8
Change	-	-	66.58%	22.62%	19.56%	-168.28%	8.69%	9.9%
Net income ¹	67.97	-84.55	-140.8	-176.1	-205.3	-536.6	-504.3	-455.8
Change	-	-	66.58%	25%	16.59%	-161.39%	6.02%	9.62%
Announcement Date	25/11/19	23/11/20	22/11/21	28/11/22	29/11/23	-	-	-

¹USD in Million

Estimates

Fiscal Period: September	2019 Q4	2020 Q1	2020 Q2	2020 Q3	2020 Q4	2021 Q1	2021 Q2	2021 Q3	2021 Q4	2022 Q1	2022 Q2	2022 Q3	2022 Q4	2023 Q1	2023 Q2	2023 Q3	2023 Q4	2024 Q1	2024 Q2	2024 Q3	2024 Q4	2025 Q1	2025 Q2	2025 Q3	2025 Q4
Net sales ¹	43.29	29.45	23.53	27.38	7.633	21.3	32.81	45.89	38.28	27.44	151.8	32.41	31.58	62.55	146.3	15.82	16.1	3.551	-	-	59.66	15.49	16.06	21.01	29.99
Change	-	-31.96%	-20.12%	16.35%	-72.12%	179.1%	54.02%	39.86%	-16.58%	-28.33%	453.25%	-78.65%	-2.58%	98.09%	133.86%	-89.18%	1.72%	-77.94%	-100%	-	-	-74.03%	3.69%	30.79%	42.76%
EBITDA ¹	-	1.518	-7.896	-	-48.34	-22.21	-26.31	-29.87	-62.38	-60.75	44.15	-70.32	-81.17	-39.44	50.83	-99.43	-104.5	-132.3	-121.7	-171.4	-133.6	-	-	-	-
Change	-	-	-	-100%	-	-54.07%	18.5%	13.52%	108.83%	-2.61%	-	-	15.44%	-51.4%	-	-	5.07%	26.62%	-8.03%	40.84%	22.04%	100%	-	-	-
EBIT ¹	9.638	-4.854	-22.24	-15.95	-50.12	-24.05	-28.23	-31.87	-64.88	-63.32	41.55	-72.91	-83.83	-42.13	48.16	-102.7	-108.3	-136.5	-126.2	-176.1	-122.5	-162.2	-162.6	-165.8	-154.8
Change	-	-	358.22%	-28.3%	214.31%	-52.01%	17.37%	12.88%	103.6%	-2.41%	-	-	14.98%	-49.74%	-	-	5.48%	26.05%	-7.58%	39.58%	30.46%	-32.39%	-0.27%	-1.93%	6.62%
Charge d'intérêts ¹	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-0.986	-0.66	-2.144	-0.805	1.404	-10	-11.1	-12.2	-13.3	-15.4
Earnings before Tax (EBT) ¹	9.638	-2.674	-19.84	-13.61	-48.43	-20.73	-26.82	-29.92	-63.37	-62.87	44.37	-72.05	-82.16	-41.79	47.68	-103.4	-109	-138.7	-127	-174	-102.6	-167.6	-167.6	-170.4	-166.4
Change	-	-	641.87%	-31.38%	255.81%	-57.19%	29.36%	11.58%	111.78%	-0.79%	-	-	14.03%	-49.13%	-	-	5.42%	27.25%	-8.43%	36.99%	41%	-63.24%	-0.03%	-1.67%	2.32%
Net income ¹	11.7	-2.674	-19.84	-13.61	-48.43	-20.73	-26.82	-29.92	-63.37	-62.87	44.37	-72.05	-85.51	-41.81	47.68	-102.9	-109.7	-132.9	-125.3	-170.8	-97.25	-170	-170.2	-173.8	-166.4
Change	-	-	641.87%	-31.38%	255.83%	-57.19%	29.36%	11.58%	111.78%	-0.79%	-	-	18.69%	-51.1%	-	-	6.54%	21.14%	-5.69%	36.31%	43.06%	-74.79%	-0.15%	-2.08%	4.21%
Announcement Date	25/11/19	05/02/20	07/05/20	05/08/20	23/11/20	04/02/21	04/05/21	05/08/21	22/11/21	02/02/22	10/05/22	04/08/22	28/11/22	06/02/23	02/05/23	07/08/23	29/11/23	06/02/24	09/05/24	08/08/24	-	-	-	-	-

¹USD in Million

Estimates

Forecast Balance Sheet: Arrowhead Pharmaceuticals, Inc.

Fiscal Period: September	2019	2020	2021	2022	2023	2024	2025	2026
Net Debt ¹	-	-315	-368	-108	-111	-183	100	287
Change	-	-	-216.83%	-129.35%	-202.78%	-265.03%	-45.36%	187%
Announcement Date	25/11/19	23/11/20	22/11/21	28/11/22	29/11/23	-	-	-

¹USD in Million

Estimates

Cash Flow Forecast: Arrowhead Pharmaceuticals, Inc.

Fiscal Period: September	2019	2020	2021	2022	2023	2024	2025	2026
CAPEX ¹	12	11.95	23.57	52.78	176.7	134.1	11.74	11.88
Change	-	-0.41%	97.19%	123.94%	234.88%	-24.12%	-91.24%	1.21%
Free Cash Flow (FCF) ¹	161	-107.3	147.7	-188.9	-330.6	-617	-444	-546.5
Change	-	-166.66%	-237.56%	-227.94%	75.02%	86.6%	-28.04%	23.1%
Announcement Date	25/11/19	23/11/20	22/11/21	28/11/22	29/11/23	-	-	-

¹USD in Million

Estimates

Forecast Financial Ratios: Arrowhead Pharmaceuticals, Inc.

Fiscal Period: September	2019	2020	2021	2022	2023	2024	2025	2026
Profitability
EBITDA Margin (%)	-	-99.12%	-101.79%	-69.11%	-79.97%	-869.91%	-361.46%	-225.7%
EBIT Margin (%)	36.25%	-105.87%	-107.77%	-73.39%	-85.16%	-906.14%	-363.33%	-217.2%
EBT Margin (%)	36.25%	-96.09%	-101.85%	-71.01%	-85.78%	-899.24%	-335.94%	-197.64%
Net margin (%)	40.27%	-96.09%	-101.85%	-72.39%	-85.27%	-870.99%	-334.9%	-197.64%
FCF margin (%)	95.4%	-121.99%	106.78%	-77.67%	-137.34%	-1,001.47%	-294.84%	-236.99%
FCF / Net Income (%)	236.9%	126.95%	-104.83%	107.3%	161.07%	114.98%	88.04%	119.91%
Profitability
ROA	-	-	-	-	-	-	-	-
ROE	-	-	-14.56%	-43.62%	-61.29%	-244.34%	-	-
Financial Health
Leverage (Debt/EBITDA)	-	-	-	-	-	-	-0.18x	-0.55x
Debt / Free cash flow	-	-	-	-	-	-	-0.23x	-0.53x
Capital Intensity
CAPEX / Current Assets (%)	7.11%	13.58%	17.04%	21.7%	73.42%	217.68%	7.8%	5.15%
CAPEX / EBITDA (%)	-	-13.7%	-16.74%	-31.4%	-91.81%	-25.02%	-2.16%	-2.28%
CAPEX / FCF (%)	7.45%	-11.13%	15.96%	-27.94%	-53.46%	-21.74%	-2.64%	-2.17%
Items per share
Cash flow per share ¹	-	-	-	-	-	-3.957	-	-
Change	-	-	-	-	-	-	-	-
Dividend per Share ¹	-	-	-	-	-	-	-	-
Change	-	-	-	-	-	-	-	-
Book Value Per Share ¹	-	-	3.919	3.761	2.528	1.049	-0.9698	-1.229
Change	-	-	-	-4.02%	-32.77%	-58.51%	-192.46%	26.69%
EPS ¹	0.69	-0.84	-1.36	-1.67	-1.92	-4.519	-4.071	-3.531
Change	-	-221.74%	61.9%	22.79%	14.97%	135.34%	-9.9%	-13.27%
Nbr of stocks (in thousands)	95,301	102,292	104,259	105,849	107,193	124,315	124,315	124,315
Announcement Date	25/11/19	23/11/20	22/11/21	28/11/22	29/11/23	-	-	-